作者
Youri Hoogstrate,Kaspar Draaisma,Santoesha A Ghisai,Levi van Hijfte,Nastaran Barin,Iris de Heer,Wouter Coppieters,Thierry P. P. van den Bosch,Anne Bolleboom,Zhenyu Gao,Arnaud J.P.E. Vincent,Latifa Karim,Manon Deckers,Martin Taphoorn,Melissa Kerkhof,Astrid Weyerbrock,Marc Sanson,Ann Hoeben,Slávka Lukacova,Giuseppe Lombardi,Sieger Leenstra,Monique C.J. Hanse,Ruth Fleischeuer,Colin Watts,Nicos Angelopoulos,Thierry Gorlia,Vassilis Golfinopoulos,Vincent Bours,Martin J. van den Bent,Pierre A. Robe,Pim J. French
摘要
A better understanding of transcriptional evolution of IDH-wild-type glioblastoma may be crucial for treatment optimization. Here, we perform RNA sequencing (RNA-seq) (n = 322 test, n = 245 validation) on paired primary-recurrent glioblastoma resections of patients treated with the current standard of care. Transcriptional subtypes form an interconnected continuum in a two-dimensional space. Recurrent tumors show preferential mesenchymal progression. Over time, hallmark glioblastoma genes are not significantly altered. Instead, tumor purity decreases over time and is accompanied by co-increases in neuron and oligodendrocyte marker genes and, independently, tumor-associated macrophages. A decrease is observed in endothelial marker genes. These composition changes are confirmed by single-cell RNA-seq and immunohistochemistry. An extracellular matrix-associated gene set increases at recurrence and bulk, single-cell RNA, and immunohistochemistry indicate it is expressed mainly by pericytes. This signature is associated with significantly worse survival at recurrence. Our data demonstrate that glioblastomas evolve mainly by microenvironment (re-)organization rather than molecular evolution of tumor cells.